To standardize and increase the applicability of the p16-CD8-Ki67 scoring system in predicting CDKN2A mutational status in individuals with clinical evidence of multiple and/or familial primary melanomas, studies with a comprehensive design are needed in larger cohorts or its integration into large-scale clinical trials could prove useful. Here, MKI67 is linked to melanoma.